Sana Biotechnology, Inc. Financials
This page shows Sana Biotechnology, Inc. (SANA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Sana Biotechnology, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Sana Biotechnology, Inc. generates $0.84 in operating cash flow (-$223.2M OCF vs -$266.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Sana Biotechnology, Inc.'s EBITDA was -$255.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4.9% from the prior year.
Sana Biotechnology, Inc. generated -$256.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 6.2% from the prior year.
Sana Biotechnology, Inc. reported -$266.8M in net income in fiscal year 2024. This represents an increase of 5.8% from the prior year.
Sana Biotechnology, Inc. earned $-1.16 per diluted share (EPS) in fiscal year 2024. This represents an increase of 20.5% from the prior year.
Sana Biotechnology, Inc. held $127.6M in cash against $0 in long-term debt as of fiscal year 2024.
Sana Biotechnology, Inc. had 224M shares outstanding in fiscal year 2024. This represents an increase of 13.2% from the prior year.
Sana Biotechnology, Inc. invested $217.6M in research and development in fiscal year 2024. This represents a decrease of 19.1% from the prior year.
Sana Biotechnology, Inc. invested $33.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 66.9% from the prior year.
SANA Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $30.1M-43.4% | $53.2M | N/A | $65.6M | N/A | $76.7M | N/A | $53.2M |
| SG&A Expenses | $10.3M-26.8% | $14.1M | N/A | $19.2M | N/A | $15.5M | N/A | $13.4M |
| Operating Income | -$43.5M+29.5% | -$61.8M | N/A | -$2.2M | N/A | -$86.2M | N/A | -$83.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$42.2M+29.7% | -$59.9M | N/A | $984K | N/A | -$85.1M | N/A | -$83.3M |
| EPS (Diluted) | $-0.16+36.0% | $-0.25 | N/A | $0.00 | N/A | $-0.45 | N/A | $-0.46 |
SANA Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $435.4M-13.1% | $501.0M-11.4% | $565.3M-10.5% | $631.4M-23.2% | $822.7M-8.4% | $898.1M-20.5% | $1.1B-8.4% | $1.2B |
| Current Assets | $161.8M+0.6% | $160.8M-24.7% | $213.5M-23.6% | $279.5M-37.1% | $444.4M-11.2% | $500.3M-10.4% | $558.1M-8.9% | $612.8M |
| Cash & Equivalents | $103.4M-19.0% | $127.6M-4.5% | $133.5M-20.7% | $168.4M-4.7% | $176.8M+8.2% | $163.3M-35.4% | $253.0M-41.7% | $433.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $140.6M0.0% | $140.6M0.0% | $140.6M0.0% | $140.6M0.0% | $140.6M0.0% | $140.6M0.0% | $140.6M0.0% | $140.6M |
| Total Liabilities | $240.1M-4.1% | $250.5M-9.8% | $277.8M+4.6% | $265.6M-17.9% | $323.4M-2.6% | $332.1M-17.2% | $400.9M-0.4% | $402.7M |
| Current Liabilities | $35.5M-21.8% | $45.4M-29.5% | $64.5M-3.2% | $66.6M-40.2% | $111.5M-2.9% | $114.8M+15.7% | $99.2M+7.9% | $92.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $195.3M-22.0% | $250.5M-12.9% | $287.5M-21.4% | $365.9M-26.7% | $499.3M-11.8% | $566.0M-22.3% | $728.5M-12.2% | $830.1M |
| Retained Earnings | -$1.8B-11.5% | -$1.6B-19.9% | -$1.3B-7.0% | -$1.2B-18.5% | -$1.1B-8.3% | -$974.4M-24.1% | -$785.4M-16.4% | -$674.6M |
SANA Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29.4M+37.6% | -$47.2M+9.2% | -$52.0M+18.2% | -$63.5M+16.5% | -$76.1M-17.4% | -$64.8M+41.1% | -$110.1M-118.1% | -$50.5M |
| Capital Expenditures | $41K-90.6% | $436K-96.9% | $14.0M+529.0% | $2.2M-51.5% | $4.6M+5.8% | $4.3M-16.4% | $5.2M-35.5% | $8.1M |
| Free Cash Flow | -$29.5M+38.1% | -$47.6M+27.9% | -$66.0M-0.3% | -$65.8M+18.5% | -$80.7M-16.7% | -$69.1M+40.0% | -$115.3M-96.9% | -$58.5M |
| Investing Cash Flow | -$48.0M-202.0% | $47.1M+207.6% | $15.3M-70.2% | $51.3M-41.9% | $88.4M+177.6% | $31.9M+143.3% | -$73.7M+60.4% | -$185.9M |
| Financing Cash Flow | $109.5M+16935.8% | $643K-62.6% | $1.7M+818.7% | $187K-82.4% | $1.1M-34.5% | $1.6M-48.0% | $3.1M+95.4% | $1.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SANA Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | 0.3% | N/A | N/A | N/A | 2.1% |
| Return on Assets | -9.7%+1.0pp | -10.7% | N/A | 0.2% | N/A | -9.5% | N/A | -6.8% |
| Current Ratio | 4.55+1.0 | 3.54+0.2 | 3.31-0.9 | 4.19+0.2 | 3.99-0.4 | 4.36-1.3 | 5.62-1.0 | 6.66 |
| Debt-to-Equity | 1.23+0.2 | 1.00+0.0 | 0.97+0.2 | 0.73+0.1 | 0.65+0.1 | 0.59+0.0 | 0.55+0.1 | 0.49 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Sana Biotechnology, Inc. profitable?
No, Sana Biotechnology, Inc. (SANA) reported a net income of -$266.8M in fiscal year 2024.
What is Sana Biotechnology, Inc.'s earnings per share (EPS)?
Sana Biotechnology, Inc. (SANA) reported diluted earnings per share of $-1.16 for fiscal year 2024. This represents a 20.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Sana Biotechnology, Inc.'s EBITDA?
Sana Biotechnology, Inc. (SANA) had EBITDA of -$255.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Sana Biotechnology, Inc.'s free cash flow?
Sana Biotechnology, Inc. (SANA) generated -$256.6M in free cash flow during fiscal year 2024. This represents a 6.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sana Biotechnology, Inc.'s operating cash flow?
Sana Biotechnology, Inc. (SANA) generated -$223.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Sana Biotechnology, Inc.'s total assets?
Sana Biotechnology, Inc. (SANA) had $501.0M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Sana Biotechnology, Inc.'s capital expenditures?
Sana Biotechnology, Inc. (SANA) invested $33.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Sana Biotechnology, Inc. spend on research and development?
Sana Biotechnology, Inc. (SANA) invested $217.6M in research and development during fiscal year 2024.
How many shares does Sana Biotechnology, Inc. have outstanding?
Sana Biotechnology, Inc. (SANA) had 224M shares outstanding as of fiscal year 2024.
What is Sana Biotechnology, Inc.'s current ratio?
Sana Biotechnology, Inc. (SANA) had a current ratio of 3.54 as of fiscal year 2024, which is generally considered healthy.
What is Sana Biotechnology, Inc.'s debt-to-equity ratio?
Sana Biotechnology, Inc. (SANA) had a debt-to-equity ratio of 1.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sana Biotechnology, Inc.'s return on assets (ROA)?
Sana Biotechnology, Inc. (SANA) had a return on assets of -53.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Sana Biotechnology, Inc.'s cash runway?
Based on fiscal year 2024 data, Sana Biotechnology, Inc. (SANA) had $127.6M in cash against an annual operating cash burn of $223.2M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sana Biotechnology, Inc.'s Piotroski F-Score?
Sana Biotechnology, Inc. (SANA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sana Biotechnology, Inc.'s earnings high quality?
Sana Biotechnology, Inc. (SANA) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.